A Phase 3 interventional study of V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) in Human Papillomavirus Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 16 in phase 3, and was the 4th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Indiana University · Sites in Kenya
Ages 9–49 · Women only · Healthy volunteers
Western Institute for Veterans Research · Sites in United States
Ages 18+
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 9 Years to 26 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 17 · Phase 4 10
First in 2009; this study’s year is marked. 1 started in 2013.
This study's enrollment of 1,518 is above the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 700 across the 31 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
38 studies in Papillomavirus Infections by Merck & Co., Inc: 1 open now, 7 under way, 6 of them phase 3. Of 30 finished, 26 (87%) have results posted.
Among the 38 studies in Papillomavirus Infections by Merck & Co., Inc, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2013, is one of 26 in phase 3, and was the 25th registered.
Merck & Co., Inc’s Papillomavirus Infections studies by the year they started, since 2000.
3 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, from their registry updates:
Among Merck & Co., Inc’s 38 in Papillomavirus Infections:
This tab as a report to print or save as PDF → With an account.
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Participants:
-Judged to be in good physical health on the basis of medical history, physical examination and laboratory results
Boys and Girls 9 to 14 Years:
-Must not have had coitarche and does not plan on becoming sexually active during the vaccination period
Women 16 to 26 Years:
Exclusion Criteria:
All Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen
Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.
Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: Month 24
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.
Time frame: Month 24
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Time frame: Month 36
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.
Time frame: Month 36
| Milestone | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Started | 301 | 301 | 301 | 301 | 314 |
| Vaccination 1 | 301 | 301 | 300 | 300 | 314 |
| Vaccination 2 | 293 | 296 | 291 | 298 | 313 |
| Vaccination 3 | 0 | 0 | 0 | 293 | 311 |
| Month 36 vaccination | 270 | 281 | 280 | 9 | 31 |
| Completed | 258 | 270 | 272 | 280 | 279 |
| Not completed | 43 | 31 | 29 | 21 | 35 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 14 | 5 | 10 | 6 | 21 |
| Withdrew: Physician decision | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 8 | 5 | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 15 | 21 | 13 | 11 | 13 |
| Withdrew: Missed last follow-up visit | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 1 | 0 | 1 |
Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen | 1657.9 (1479.6 to 1857.6) | 1557.4 (1391.5 to 1743.1) | 2678.8 (2390.2 to 3002.1) | 1496.1 (1334.1 to 1677.8) | 770.9 (684.8 to 867.9) |
Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 99.6 (97.9 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 99.2 (97.2 to 99.9) | 99.6 (97.7 to 100) |
Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 1388.9 (1240.4 to 1555.3) | 1423.9 (1273.2 to 1592.3) | 2941.8 (2626.6 to 3294.9) | 1306.3 (1165.5 to 1464.0) | 580.5 (516.0 to 653.0) |
Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 8004.9 (7160.5 to 8948.8) | 8474.8 (7582.4 to 9472.3) | 14329.3 (12796.4 to 16045.9) | 6996.0 (6254.1 to 7825.8) | 3154.0 (2807.1 to 3543.7) |
Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 1872.8 (1651.6 to 2123.6) | 1860.9 (1641.1 to 2110.2) | 2810.4 (2474.9 to 3191.3) | 2049.3 (1806.4 to 2324.8) | 761.5 (670.8 to 864.5) |
Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 1436.3 (1272.1 to 1621.8) | 1498.2 (1326.5 to 1692.0) | 2117.5 (1873.7 to 2393.1) | 1748.3 (1548.1 to 1974.5) | 572.1 (505.8 to 647.2) |
Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 1030.0 (920.4 to 1152.7) | 1040.0 (928.9 to 1164.3) | 2197.5 (1961.9 to 2461.3) | 796.4 (712.0 to 890.9) | 348.1 (311.5 to 389.1) |
Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 357.6 (313.7 to 407.6) | 352.3 (309.0 to 401.7) | 417.7 (365.9 to 476.9) | 661.7 (580.6 to 754.1) | 213.6 (187.7 to 243.2) |
Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 581.1 (521.9 to 647.1) | 640.4 (575.2 to 713.0) | 1123.4 (1008.1 to 1251.9) | 909.9 (817.6 to 1012.5) | 364.2 (327.0 to 405.6) |
Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 1251.2 (1119.6 to 1398.4) | 1325.7 (1186.2 to 1481.6) | 2444.6 (2185.2 to 2734.9) | 1229.3 (1100.7 to 1373.0) | 491.1 (438.6 to 549.8) |
Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 100 (98.6 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 99.6 (97.8 to 100) | 99.6 (97.7 to 100) |
Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 100 (98.7 to 100) | 100 (98.7 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 99.6 (97.8 to 100) |
Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 100 (98.7 to 100) | 100 (98.7 to 100) | 100 (98.6 to 100) | 99.6 (98.0 to 100) | 98.5 (96.2 to 99.6) |
Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 99.6 (98.0 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 99.6 (97.9 to 100) |
Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 99.6 (98.0 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 100 (98.7 to 100) | 99.6 (98.0 to 100) |
Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 99.3 (97.4 to 99.9) | 99.3 (97.4 to 99.9) | 100 (98.6 to 100) | 99.3 (97.4 to 99.9) | 97.9 (95.4 to 99.2) |
Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 99.6 (98.0 to 100) | 100 (98.7 to 100) | 100 (98.6 to 100) | 99.6 (98.0 to 100) | 99.6 (98.0 to 100) |
Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen | 100 (98.6 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 99.6 (98.0 to 100) | 99.6 (97.9 to 100) |
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Anti-HPV Type 6 | 260.7 (231.5 to 293.6) | 209.1 (185.9 to 235.1) | 574.0 (509.6 to 646.5) | 300.7 (266.8 to 339.0) | 153.2 (135.4 to 173.5) |
| Anti-HPV Type 11 | 169.8 (150.5 to 191.7) | 150.6 (133.6 to 169.7) | 443.7 (392.9 to 501.0) | 201.9 (178.7 to 228.1) | 98.3 (86.6 to 111.6) |
| Anti-HPV Type 16 | 900.5 (788.0 to 1028.9) | 801.0 (701.5 to 914.6) | 2316.2 (2023.5 to 2651.4) | 1041.3 (910.8 to 1190.4) | 461.6 (401.2 to 531.0) |
| Anti-HPV Type 18 | 196.8 (174.9 to 221.6) | 169.6 (150.7 to 190.8) | 380.8 (337.9 to 429.1) | 255.8 (227.2 to 288.0) | 122.2 (108.4 to 137.7) |
| Anti-HPV Type 31 | 160.6 (140.8 to 183.3) | 139.1 (122.0 to 158.7) | 312.8 (273.9 to 357.1) | 260.6 (228.4 to 297.3) | 89.6 (78.4 to 102.5) |
| Anti-HPV Type 33 | 131.2 (116.9 to 147.2) | 121.5 (108.3 to 136.4) | 341.7 (304.3 to 383.6) | 120.8 (107.7 to 135.4) | 61.3 (54.6 to 68.7) |
| Anti-HPV Type 45 | 37.8 (33.2 to 43.0) | 31.9 (28.0 to 36.3) | 62.3 (54.7 to 71.1) | 86.9 (76.4 to 98.9) | 30.7 (27.0 to 34.9) |
| Anti-HPV Type 52 | 85.1 (76.4 to 94.7) | 80.9 (72.7 to 90.0) | 199.4 (179.0 to 222.2) | 150.4 (135.2 to 167.4) | 73.7 (66.1 to 82.1) |
| Anti-HPV Type 58 | 155.4 (138.0 to 175.1) | 149.8 (133.1 to 168.6) | 380.2 (337.3 to 428.6) | 183.7 (163.3 to 206.7) | 76.8 (68.0 to 86.7) |
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Anti-HPV Type 6 | 98.4 (96.0 to 99.6) | 96.9 (94.0 to 98.7) | 99.2 (97.2 to 99.9) | 99.6 (97.8 to 100) | 94.0 (90.1 to 96.7) |
| Anti-HPV Type 11 | 98.0 (95.4 to 99.4) | 95.8 (92.6 to 97.9) | 99.6 (97.8 to 100) | 98.8 (96.5 to 99.8) | 94.8 (91.1 to 97.3) |
| Anti-HPV Type 16 | 98.9 (96.7 to 99.8) | 99.6 (97.9 to 100) | 100 (98.6 to 100) | 99.6 (97.9 to 100) | 99.6 (97.7 to 100) |
| Anti-HPV Type 18 | 98.5 (96.2 to 99.6) | 95.9 (92.8 to 97.9) | 98.9 (96.7 to 99.8) | 99.2 (97.3 to 99.9) | 95.0 (91.6 to 97.3) |
| Anti-HPV Type 31 | 97.0 (94.2 to 98.7) | 94.8 (91.4 to 97.1) | 98.5 (96.2 to 99.6) | 97.7 (95.2 to 99.2) | 91.5 (87.4 to 94.6) |
| Anti-HPV Type 33 | 97.8 (95.2 to 99.2) | 96.6 (93.7 to 98.4) | 99.2 (97.3 to 99.9) | 98.9 (96.8 to 99.8) | 94.8 (91.4 to 97.1) |
| Anti-HPV Type 45 | 88.4 (84.0 to 92.0) | 85.9 (81.1 to 89.8) | 93.9 (90.3 to 96.5) | 96.7 (93.8 to 98.5) | 82.7 (77.6 to 87.0) |
| Anti-HPV Type 52 | 96.6 (93.7 to 98.4) | 95.2 (91.9 to 97.4) | 99.2 (97.3 to 99.9) | 99.3 (97.3 to 99.9) | 97.3 (94.6 to 98.9) |
| Anti-HPV Type 58 | 98.9 (96.7 to 99.8) | 99.6 (97.9 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | 96.0 (92.9 to 98.1) |
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
| mMU/mL | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Anti-HPV Type 6 | 209.6 (184.9 to 237.6) | 160.1 (141.9 to 180.7) | 401.2 (354.8 to 453.7) | 232.2 (205.1 to 263.0) | 133.8 (117.3 to 152.7) |
| Anti-HPV Type 11 | 133.7 (117.6 to 152.1) | 115.2 (101.8 to 130.3) | 308.2 (271.8 to 349.6) | 159.1 (140.0 to 180.7) | 82.9 (72.4 to 94.9) |
| Anti-HPV Type 16 | 673.8 (582.8 to 779.1) | 592.6 (514.7 to 682.4) | 1534.3 (1328.8 to 1771.5) | 792.4 (686.7 to 914.4) | 368.9 (316.4 to 430.0) |
| Anti-HPV Type 18 | 158.9 (140.8 to 179.4) | 141.7 (125.9 to 159.4) | 276.4 (245.3 to 311.6) | 206.5 (183.3 to 232.7) | 104.1 (92.0 to 117.8) |
| Anti-HPV Type 31 | 127.8 (111.4 to 146.5) | 106.9 (93.5 to 122.1) | 218.0 (190.6 to 249.4) | 205.9 (180.0 to 235.5) | 74.6 (64.8 to 85.9) |
| Anti-HPV Type 33 | 106.0 (94.1 to 119.5) | 95.7 (85.1 to 107.5) | 240.4 (213.8 to 270.3) | 95.5 (85.0 to 107.3) | 52.2 (46.3 to 58.9) |
| Anti-HPV Type 45 | 30.6 (26.9 to 35.0) | 26.8 (23.6 to 30.4) | 43.6 (38.3 to 49.7) | 66.1 (58.1 to 75.2) | 27.3 (23.9 to 31.1) |
| Anti-HPV Type 52 | 66.2 (59.1 to 74.0) | 63.4 (56.8 to 70.7) | 143.2 (128.3 to 159.9) | 115.9 (103.9 to 129.3) | 61.5 (54.8 to 68.9) |
| Anti-HPV Type 58 | 125.8 (111.1 to 142.5) | 119.2 (105.6 to 134.5) | 265.3 (234.8 to 299.8) | 143.0 (126.7 to 161.5) | 64.7 (56.9 to 73.6) |
Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.
| Percentage of participants | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Anti-HPV Type 6 | 95.3 (91.8 to 97.7) | 91.3 (87.2 to 94.5) | 99.2 (97.1 to 99.9) | 97.9 (95.2 to 99.3) | 92.1 (87.6 to 95.3) |
| Anti-HPV Type 11 | 94.1 (90.2 to 96.7) | 92.9 (89.1 to 95.8) | 99.2 (97.1 to 99.9) | 98.8 (96.4 to 99.7) | 92.1 (87.6 to 95.3) |
| Anti-HPV Type 16 | 97.2 (94.3 to 98.9) | 98.5 (96.2 to 99.6) | 100 (98.6 to 100) | 99.2 (97.2 to 99.9) | 98.2 (95.5 to 99.5) |
| Anti-HPV Type 18 | 95.6 (92.2 to 97.8) | 94.3 (90.7 to 96.8) | 97.6 (94.9 to 99.1) | 97.3 (94.4 to 98.9) | 90.8 (86.4 to 94.1) |
| Anti-HPV Type 31 | 94.0 (90.2 to 96.6) | 91.2 (87.1 to 94.3) | 96.5 (93.5 to 98.4) | 97.7 (95.0 to 99.1) | 86.0 (80.8 to 90.1) |
| Anti-HPV Type 33 | 94.0 (90.3 to 96.6) | 96.9 (94.1 to 98.7) | 99.2 (97.2 to 99.9) | 98.1 (95.6 to 99.4) | 91.9 (87.7 to 95.0) |
| Anti-HPV Type 45 | 83.6 (78.4 to 88.0) | 81.4 (76.1 to 85.9) | 87.9 (83.3 to 91.7) | 91.2 (87.1 to 94.3) | 77.8 (72.1 to 82.8) |
| Anti-HPV Type 52 | 93.5 (89.7 to 96.3) | 93.9 (90.3 to 96.5) | 98.8 (96.6 to 99.8) | 97.7 (95.1 to 99.2) | 95.0 (91.4 to 97.4) |
| Anti-HPV Type 58 | 98.0 (95.3 to 99.3) | 99.2 (97.3 to 99.9) | 100 (98.6 to 100) | 98.8 (96.7 to 99.8) | 94.8 (91.1 to 97.3) |
Collected over Serious Adverse Events: Up to Month 37; Non-injection site adverse events: up to Day 15 following any vaccination; Injection site adverse events: up to Day 5 following any vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Girls 9 to 14 Years V503 at Months 0 and 6 | 0/294 (0%) | 6/294 (2%) | 53/294 (18%) |
| Boys 9 to 14 Years V503 at Months 0 and 6 | 0/296 (0%) | 9/296 (3%) | 32/296 (10.8%) |
| Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | 0/293 (0%) | 6/293 (2%) | 46/293 (15.7%) |
| Girls 9 to 14 Years V503 at Months 0, 2, and 6 | 1/300 (0.3%) | 6/300 (2%) | 55/300 (18.3%) |
| Young Women 16 to 26 Years V503 at Months 0, 2, and 6 | 0/313 (0%) | 11/313 (3.5%) | 90/313 (28.8%) |
| Event | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Abortion inducedSurgical and medical procedures | 0/294 | 0/296 | 0/293 | 0/300 | 4/313 |
| Abdominal painGastrointestinal disorders | 2/294 | 0/296 | 0/293 | 0/300 | 1/313 |
| AppendicitisInfections and infestations | 1/294 | 1/296 | 1/293 | 1/300 | 0/313 |
| Forearm fractureInjury, poisoning and procedural complications | 0/294 | 0/296 | 1/293 | 0/300 | 0/313 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/294 | 0/296 | 1/293 | 0/300 | 0/313 |
| GastritisGastrointestinal disorders | 0/294 | 0/296 | 1/293 | 0/300 | 0/313 |
| Oral herpesInfections and infestations | 0/294 | 0/296 | 1/293 | 0/300 | 0/313 |
| RadiculopathyNervous system disorders | 0/294 | 0/296 | 1/293 | 0/300 | 0/313 |
| Dengue feverInfections and infestations | 1/294 | 0/296 | 0/293 | 0/300 | 0/313 |
| PharyngitisInfections and infestations | 1/294 | 0/296 | 0/293 | 0/300 | 0/313 |
| Event | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 49/294 | 28/296 | 41/293 | 53/300 | 80/313 |
| HeadacheNervous system disorders | 8/294 | 9/296 | 7/293 | 7/300 | 16/313 |
| Age, Continuous(Years) | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 | Total |
|---|---|---|---|---|---|---|
| Mean | 11.4 ± 1.7 | 11.5 ± 1.7 | 11.4 ± 1.6 | 11.4 ± 1.7 | 21.0 ± 2.7 | 13.4 ± 4.3 |
| Age, Customized(Participants) | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 | Total |
|---|---|---|---|---|---|---|
| Between 9 and 10 years | 100 | 98 | 100 | 101 | 0 | 399 |
| Between 11 and 12 years | 102 | 102 | 106 | 100 | 0 | 410 |
| Between 13 and 14 years | 99 | 101 | 95 | 100 | 0 | 395 |
| Between 16 and 26 years | 0 | 0 | 0 | 0 | 314 | 314 |
| Sex: Female, Male(Participants) | Girls 9 to 14 Years V503 at Months 0 and 6 | Boys 9 to 14 Years V503 at Months 0 and 6 | Girls and Boys 9 to 14 Years V503 at Months 0 and 12 | Girls 9 to 14 Years V503 at Months 0, 2, and 6 | Young Women 16 to 26 Years V503 at Months 0, 2, and 6 | Total |
|---|---|---|---|---|---|---|
| Female | 301 | 0 | 151 | 301 | 314 | 1067 |
| Male | 0 | 301 | 150 | 0 | 0 | 451 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2013 to primary completion in Jun 2015, 18 months.
Results were first posted in Apr 2016, 10 months after primary completion.
Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 18 months is below that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent